We have identified KDM5D as a male specific gene which mediates Kras driven colon cancer metastasis. We will elucidate the role of KDM5D in CRC progression and to define KDM5D target genes in mediating the metastasis process. We have also established KDM5D transgenic mice in a colon cancer model and its role will be further investigated in vivo.
In collaboration with Dr. Chun Li at MD Anderson Cancer Center, we will focus on the effect of irreversible electroporation on immunotherapy. We will explore a combination of IRE+PD1 +anti MDSC agents in pancreatic cancer liver metastasis model and tumor microenvironments will be studied post treatment using spatial transcriptomics.
Current Research Funding
NIH/NCI 1R01CA231349 (Wang, PI)
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM
NIH/NCI 1R01CA258540 (Li and Wang, MPI)
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma
NIH/NCI 1RO1 CA262798-01A1 (Wang, PI)
Sex specific epigenetic regulation of colon cancer metastasis.
DOD (Wang, PI)
Elucidating and therapeutic targeting of prostate bone metastasis
Liao W. et al., KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21. PMID: 30905761; PMCID: PMC6467776.
Chen P. et al., Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment. Cancer Discov. 2020 Mar;10(3):371-381. doi: 10.1158/2159-8290.CD-19-0400. Epub 2020 Jan 9. PMID: 31919052; PMCID: PMC7058515.
Zhao D. et al., Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020 Sep;10(9):1374-1387. doi: 10.1158/2159-8290.CD-19-1352. Epub 2020 May 8. PMID: 32385075; PMCID: PMC7483306.
Lee R. et al., Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer. Cancer Discov. 2022 Jul 6;12(7):1702-1717. doi: 10.1158/2159-8290.CD-21-0680. PMID: 35537038; PMCID: PMC9262860.
Gulhati, P. et al.,Targeting T cell checkpoints 41BB and LAG3 and Myeloid cell CXCR1/2 results in anti-tumor immunity and durable response in pancreatic cancer. Nature Cancer 2022 Dec 30. PMID: 36585453